Analyzing...
Loading company...
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,408 full-time employees. The company went IPO on 2004-04-17. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. The company has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹16,927 Cr revenue.
COGS 33.6%, employees 20.7%.
“biosimilar revenues for q two f y twenty six stood at 2,721 crores, representing a 25% year on year increase.”
“Operating revenues stood at 4,296 crores, up 20% year on year as I just mentioned.”
“Core EBITDA was 1,218 crores, which is up 23% year on year with a margin of 28%.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 1.1%▼ | 10.3% |
| ROCE | 2.9%▼ | 13.7% |
| Net Margin | 2.2%▼ | 7.6% |
| EBITDA Margin | 19.7%▲ | 15.4% |
| Debt To Equity | 0.44x▲ | 0.15x |
| Rev Growth 3yr | 14.3%▲ | 10.0% |
| EPS Growth 3yr | -14.8%▼ | 16.0% |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹16,927 Cr +10.9% | ₹15,262 Cr +3.4% | ₹14,756 Cr +32.1% | ₹11,174 Cr +36.5% | ₹8,184 Cr +15.2% | ₹7,106 Cr +11.6% | ₹6,367 Cr +15.5% | ₹5,514 Cr |
| Other Income | ₹343 Cr -71.7% | ₹1,208 Cr +39.6% | ₹866 Cr +130.2% | ₹376 Cr +76.7% | ₹213 Cr -16.4% | ₹255 Cr +57.7% | ₹161 Cr +11.8% | ₹144 Cr |
| Total Income | ₹17,270 Cr +4.9% | ₹16,470 Cr +5.4% | ₹15,621 Cr +35.2% | ₹11,550 Cr +37.6% | ₹8,397 Cr +14.1% | ₹7,360 Cr +12.7% | ₹6,529 Cr +15.4% | ₹5,659 Cr |
| COGS | ₹5,691 Cr +9.5% | ₹5,198 Cr +6.1% | ₹4,898 Cr +33.7% | ₹3,663 Cr +34.8% | ₹2,718 Cr +23.1% | ₹2,209 Cr +7.6% | ₹2,052 Cr +8.2% | ₹1,897 Cr |
| ₹16,436 Cr +12.0% | ₹14,680 Cr +4.9% | ₹14,000 Cr +37.3% | ₹10,195 Cr +43.7% | ₹7,096 Cr +14.0% | ₹6,226 Cr +15.7% | ₹5,381 Cr +16.0% | ₹4,639 Cr | |
| Profit Before Tax | ₹448 Cr -76.3% | ₹1,887 Cr +17.2% | ₹1,609 Cr +51.2% | ₹1,064 Cr -10.6% | ₹1,190 Cr +3.8% | ₹1,147 Cr -5.6% | ₹1,215 Cr +0.1% | ₹1,214 Cr |
| Exceptional Items | (₹386 Cr) ↓ Decline | ₹97 Cr ↑ Recovery | (₹12 Cr) +96.0% | (₹291 Cr) -162.3% | (₹111 Cr) ↓ Decline | ₹13 Cr -81.3% | ₹68 Cr -65.3% | ₹195 Cr |
| ₹79 Cr -82.7% | ₹457 Cr +101.1% | ₹227 Cr -10.5% | ₹254 Cr +20.1% | ₹212 Cr -4.5% | ₹222 Cr -29.7% | ₹315 Cr +48.4% | ₹212 Cr | |
| Net Profit | ₹369 Cr -74.2% | ₹1,429 Cr +10.1% | ₹1,298 Cr +101.8% | ₹643 Cr -16.7% | ₹772 Cr -8.8% | ₹846 Cr -2.8% | ₹871 Cr -13.1% | ₹1,003 Cr |
| Profit (Owners) | ₹386 Cr -61.9% | ₹1,013 Cr -0.9% | ₹1,023 Cr +121.0% | ₹463 Cr -28.6% | ₹648 Cr -12.4% | ₹741 Cr -1.0% | ₹748 Cr -17.4% | ₹905 Cr |
| Minority Interest | (₹17 Cr) ↓ Decline | ₹416 Cr +51.1% | ₹275 Cr +52.7% | ₹180 Cr +46.3% | ₹123 Cr +16.6% | ₹106 Cr -13.9% | ₹123 Cr +26.1% | ₹97 Cr |
| Other Comprehensive Income | ₹2,044 Cr +368.1% | ₹437 Cr +12.9% | ₹387 Cr +404.8% | ₹77 Cr -30.5% | ₹110 Cr -48.6% | ₹215 Cr ↑ Recovery | (₹188 Cr) -160.2% | (₹72 Cr) |
| EPS | ₹2.72 | ₹8.44 | ₹8.52 | ₹3.85 | ₹5.40 | ₹6.17 | ₹6.24 | ₹7.54 |
| Diluted Shares | ₹162 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr |
Biocon Limited has informed the Exchange regarding 'Company Statement'.
Biocon Limited has informed the Exchange about Schedule of meet
Mylan Inc. has Submitted to the Exchange a copy of Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.
Biocon Limited has informed the Exchange about Copy of Newspaper Publication
Biocon Limited has informed the Exchange regarding 'Company Statement'.
Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 06, 2026
Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Biocon Limited has informed the Exchange regarding a press release dated July 09, 2026, titled " Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili , a Biosimil...
Biocon Limited has informed the Exchange about Copy of Newspaper Publication
Biocon Limited has informed the Exchange about Investor Presentation
Biocon Limited has informed the Exchange about Schedule of meet
Biocon Limited has informed the Exchange about Schedule of meet
Biocon Limited has informed the Exchange about Transcript
Biocon Limited has informed the Exchange regarding 'Company Statement'.